Jeena Sikho Lifecare (JSLL) Q2 23/24 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 23/24 earnings summary
23 Oct, 2026Executive summary
H1 FY23/24 revenue from operations was Rs 15,736.00 lacs, versus Rs 8,650.47 lacs in H1 FY22/23; profit for the period was Rs 3,182.69 lacs versus Rs 1,121.15 lacs.
Standalone results were unaudited and reviewed; the auditor reported no matters indicating material misstatement or non-compliance with disclosure requirements.
Financial highlights
Total income was Rs 15,884.97 lacs versus Rs 8,742.57 lacs; other income was Rs 148.97 lacs versus Rs 92.10 lacs.
Total expenses were Rs 11,515.45 lacs versus Rs 7,205.81 lacs.
Profit before tax was Rs 4,369.52 lacs versus Rs 1,536.76 lacs; profit after tax was Rs 3,182.69 lacs versus Rs 1,121.15 lacs.
Net cash from operating activities was Rs 2,261.71 lacs versus Rs 192.99 lacs in H1 FY22/23.
Segment performance
Operations comprise one segment: trading of Ayurvedic medicines and providing Ayurvedic therapies; no separate reporting segments apply.
Latest events from Jeena Sikho Lifecare
- FY23 revenue reached ₹204 crore as a 119-site network supported expansion.JSLL
Investor presentation - Asset-light Ayurveda services and product sales supported expansion and higher reported revenue.JSLLInvestor presentation
- Q2 revenue grew 66% as margins, patient volumes and hospital capacity advanced.JSLLQ2 25/26
- FY24 revenue grew 59% as profits doubled and operational capacity expanded.JSLLQ4 23/24
- H1FY25 revenue and PAT rose as expansion costs weighed on EBITDA margin.JSLLQ2 24/25
- FY25 revenue rose 45%, with 87% IPD growth as capacity expanded to 1,600 beds.JSLLQ4 24/25
- Standalone Q3 revenue rose 92%, with PAT up 405% and 475+ beds in development.JSLLQ3 25/26
- Revenue reached ₹17,428.59 lakh, with standalone PAT of ₹5,131.14 lakh.JSLLQ1 25/26
- Consolidated FY26 net profit reached ₹22,169.81 lakh; proposed dividend is ₹4.50 per share.JSLLQ4 25/26